Hansoh Pharmaceutical (03692.HK): Ameile® Granted Inclusion of Two New Indications in China's 2025 National Reimbursement Drug List

Hansoh Pharma (03692) announced that the group's innovative drug Ameile^®Two New Indications Successfully Included in the New Edition of the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalog (2025)" (2025 National Medical Insurance Catalog) - Sanofi^®, Hengmu^®All indications for renewal have been included in the 2025 National Medical Insurance Catalog, and the new version of the national catalog will be officially implemented on January 1, 2026.

1. Aumetinib Mesylate Tablets (Brand Name: Almela)^®) Two new indications approved in March and April 2025 have been included in the 2025 National Medical Insurance Catalog: Treatment of adult patients with Stage II-IIIB non-small cell lung cancer (NSCLC) who have previously undergone surgical resection and have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21(L858R) substitution mutations; Treatment of adult patients with locally advanced, unresectable (Stage III) NSCLC who have not experienced disease progression during or after platinum-based chemoradiotherapy and have EGFR exon 19 deletions or exon 21(L858R) substitution mutations.

2. Pemostamab Injection (Trade name: Sunrolle^®) Both indications have been renewed and included in the 2025 National Medical Insurance Catalog: for the treatment of anemia caused by chronic kidney disease, including: 1. Adult non-dialysis patients not receiving erythropoiesis-stimulating agent (ESA) therapy; 2. Adult dialysis patients receiving short-acting erythropoietin therapy.

3. Amibetanofavir Tablets (Trade Name: Hengmu)^®) Renewal inclusion in the 2025 National Medical Insurance Catalog for adult patients with chronic hepatitis B.

In addition, the innovative drug Flumatinib Mesylate Tablets (trade name: HANSOH XINFU) of this group^®), Polyethylene Glycol Lozneseptide Injection (Trade Name: Fulai Mei^®), Inebilizumab Injection (Trade Name: Xinyue^®) for NMOSD, Aumetinib Mesylate Tablets (Brand Name: Almela^®) for the treatment of first-line and second-line NSCLC, both are currently within the validity period of the National Medical Insurance Catalog agreement, which is valid until December 31, 2026; Morpholine Nitroazole Sodium Chloride Injection (brand name: Mailingda^®) has been included in the Class B of the National Medical Insurance Regular Catalog.